Authored By: Sarah
11 Jul 2024

 Sepsis Therapeutics Market to grow by USD 1.42 billion between 2024-2028

According to a research report “ Sepsis Therapeutics Market” by Application (Hospitals, Clinics, Others) Type (Antimicrobial therapy, Adjunctive therapy) Geography (North America, Europe, APAC, South America, Middle East and Africa)- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 1.42 billion at a CAGR of  6.98% during the forecast period. The global sepsis challenge is underscored by the CDC's report of 1.7 million annual adult cases and 350,000 deaths in the US, surpassing those from opioid overdoses, breast cancer, and prostate cancer. In the UK, an estimated 245,000 cases occur yearly. With heightened awareness and diagnosis, sepsis cases have risen, making the development of effective sepsis therapeutics a priority. Sepsis, a life-threatening condition, can stem from bacterial, viral, or fungal infections..

Browse market data tables, figures, and in-depth TOC on “Sepsis Therapeutics Market” by Application (Hospitals, Clinics, Others) Type (Antimicrobial therapy, Adjunctive therapy) Geography (North America, Europe, APAC, South America, Middle East and Africa) Global Forecast to 2028.

 View detailed Table of Content- Click here

By Application, the Hospitals segment is projected to dominate the market size in 2024.

In the sepsis therapeutics market, antimicrobial agents represent a significant segment due to their role in combating the underlying infectious agents during sepsis treatment. Broad-spectrum antibiotics, such as ceftriaxone and meropenem, are widely utilized to target a diverse range of bacterial pathogens. Narrow-spectrum antibiotics, like vancomycin, are employed when a specific pathogen is identified. Antivirals, such as oseltamivir, and antifungals, like fluconazole, address viral and fungal sources, respectively. Rapid and effective distribution throughout the body is ensured through various administration routes, including intravenous. Timely initiation of antimicrobial therapy is crucial, as it directly impacts the success of sepsis management by halting infection progression.

By Type, Antimicrobial therapy  segment is expected to hold the largest market size for the year 2024.

In the dynamic and complex sepsis therapeutics market, hospitals serve as pivotal business entities, spearheading the diagnosis, treatment, and management of sepsis cases. Institutions such as the Mayo Clinic and Cleveland Clinic, recognized for their patient-centric approaches and innovative medical practices, epitomize the comprehensive care offered to sepsis patients. Hospitals administer sepsis therapeutics in various departments, including emergency rooms, ICUs, and surgical wards, highlighting the urgency and intricacy of sepsis cases. These establishments prioritize protocols for swift identification, aggressive treatment, and continuous monitoring, reaffirming their indispensable role in combating sepsis within the market landscape.

North America is forecasted to hold the largest market size by region in 2024.

The North American sepsis therapeutics market holds significant clout on the global stage, driven primarily by the US and Canada. This region's dominance is attributed to its sophisticated healthcare infrastructure, pioneering medical research, and stringent regulatory environment. Notable contributors to sepsis diagnosis and treatment advancements include esteemed institutions like the Mayo Clinic and Johns Hopkins Hospital in the US. The high prevalence of sepsis, coupled with heightened awareness among healthcare professionals and the public, fuels the demand for efficacious therapeutics, thereby bolstering market expansion in North America.

The Sepsis Therapeutics Market t growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Adrenomed AG
  • AM Pharma BV
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • bioMerieux SA
  • CytoSorbents Corp.
  • F. Hoffmann La Roche Ltd.
  • Hikma Pharmaceuticals Plc
  • Inotrem S.A.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Spectral Medical Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Sepsis Therapeutics Market encompasses a range of diagnostic tests and therapeutics used in the treatment of sepsis, a life-threatening condition caused by bacterial or viral infections. The prevalence of sepsis is a significant concern in healthcare institutions, with ICU patients being at a higher risk. Fortum, Zinacef, Zinnat, and Sandoz are among the companies engaged in the development and financing of sepsis therapeutics. Sepsis mortality rate remains high, with Sepsis Canada and the Canadian Institutes collaborating on clinical trial activities to address this issue. Ceftobiprole medocaril and Cephalosporins are among the therapeutics used in sepsis treatment. Government funding plays a crucial role in supporting company activities in this field. Matinas BioPharma is another company involved in the development of oral aminoglycoside therapeutics for various infections, including sepsis. The market for sepsis therapeutics is expansive, addressing urinary tract infections, influenza, pneumonia, and other bacterial and viral infections.

Market Research Overview

The sepsis therapeutics market encompasses the development and provision of clinical trials for therapeutic medications aimed at managing sepsis in various populations, including the geriatric population. These medications are designed to reduce septic shock, fatalities, and hospitalizations, particularly in high-risk groups such as those with malignancies, hypertension, type 2 diabetes, self-reported morbidity, and lower-back symptoms. Companies like Matinas BioPharma, GSK, Sandoz, and Fortum are actively engaged in this field, focusing on innovative treatments like Xigris, Zinacef, Zinnat, Ceftobiprole medocaril, and Oral aminoglycoside. The market also includes therapeutics for viral and bacterial infections, such as influenza, pneumonia, and urinary tract infections. Government funding through Canadian Institutes and Clinical trial activities in Southeast Asia and Sepsis Canada contribute significantly to the advancement of sepsis therapeutics. The financing and healthcare utilization aspects of sepsis treatment are crucial, with ICU patients and hospitalizations being major concerns in the context of sepsis mortality rate and healthcare institutions' company activities.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio